Using Synthetic Biology to Create Therapeutic Solutions
This revolutionary technology shows promise for addressing a myriad of challenges in medicine, but ethical dilemmas remain.
Plasma’s Pivotal Role in Cancer Therapy
Known as liquid gold, human plasma is proving to be a valuable ally in the fight against cancer.
Complement Inhibitors as Therapeutic Agents for Autoimmune Disease
While still in their early stages of research, FDA has approved more than a dozen complement inhibitors to treat various conditions, and there is hope that more will be on the horizon to treat others.
Researchers Transform Cancer Therapy to Make it 20,000 Times More Effective
Researchers re-engineered the structure of the commonly ussed chemotherapy drug 5-fluorouracil (5FU) into that of a “spherical nucleic acid” — a nanostructure that weaves the drug directly into DNA strands coating tiny spheres, making its cancer cell-killing ability 20,000 more effective, while also reducing its toxicity.
Study Reveals Potential New Way to Treat Autoimmune Disease
A new study by researchers at Swansea University has revealed a new way to potentially treat certain autoimmune diseases by targeting a protein that helps regulate energy production in immune cells.
Combination Immunotherapy Helps Overcome Melanoma Treatment Resistance
Early data from a Phase II clinical trial show a combination of immunotherapy medications can activate a robust immune response and help overcome treatment resistance in patients with refractory melanoma.
Efgartigimod Treatment Increases Spending for CIDP Patients
A new study has found that introducing efgartigimod alfa as a treatment option in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who are currently receiving subcutaneous immune globulin (IG) or intravenous IG would result in substantially increased spending in the treatment of CIPD.
Therapeutic Plasma Exchange: A Promising New Treatment for Sepsis and Septic Shock
Therapeutic plasma exchange may improve outcomes for patients diagnosed with sepsis or septic shock, but funding is needed to conduct needed clinical trials.
FDA Approves Implantable Device to Treat RA Patients
SetPoint System, a neuroimmune modulation device, has been approved by the U.S. Food and Drug Administration to treat adults with moderately to severely active rheumatoid arthritis who have had an inadequate response, loss of response or intolerance to one or more biological or targeted synthetic disease-modifying anti-rheumatic drugs.
Takeda’s New Devices for Hyqvia Infusion Can Reduce Preparation Steps By Up to One-Half
The U.S. Food and Drug Administration has granted 510(k) clearance to Takeda’s HyHub and HyHub Duo for patients 17 years of age and older that allow HYQVIA [immune globulin infusion (human), 10% with recombinant human hyaluronidase] to be transferred from vials without using a needle in a home environment or clinical setting.